CTOs on the Move

Tmunity

www.tmunity.com

 
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.tmunity.com
  • 3020 Market Street Suite 535
    Philadelphia, PA USA 19104
  • Phone: 215.966.1600

Executives

Name Title Contact Details
Jason Krentz
 Chief Technology Officer and Head of Technical Operations Profile

Funding

Tmunity raised $100M on 01/23/2018
Tmunity raised $35M on 04/19/2018
Tmunity raised $75M on 10/31/2019

Similar Companies

Somatic Therapies

Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MultiPlan

MultiPlan is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tissue Gnostics

Tissue Gnostics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gliknik

Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.

CARsgen

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.